IKK/NF-B disrupts adult hypothalamic neural stem cells to mediate a neurodegenerative mechanism of dietary obesity and pre-diabetes
(2024d)
We support clinics that wants an AOD 9604 option for patient programs, with clear education on what it is, what it is not, and how to set expectations responsibly
Under current FDA guidance, a 503A pharmacy can compound a GLP-1 medication for a specific patient only when the prescriber documents a "significant difference" - a genuine clinical reason why the compounded formulation serves that patient's specific medical need in a way the commercially available FDA-approved product cannot
Join Delilah is a weight management program designed specifically for women, offering a tailored plan that combines GLP-1 treatments like semaglutide and tirzepatide with ongoing support
Rolker, H., Maldonado, A., Soto-Mndes, M., Melse-Boonstra, A